Company Profile

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix™, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain. Following a breakthrough in microbiome research, SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix™ platform can improve the barrier effect of skin models – from moisture retention to anti-infection to repair. SkinBioTherapeutics is targeting three specific markets; cosmetics, infection control and eczema. In each of these areas the Company intends to exemplify its technology in human studies. The most advanced programme is focused on creating an ingredient for the cosmetics industry to treat sensitive skin. The business strategy is to outlicense its programmes at proof of concept. SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix™. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI). The Company is based in Manchester, UK.